Lexicon Pharmaceuticals | LXRX - Zysk Brutto Na Sprzedaży





Zysk Brutto Na Sprzedaży Zmiana Data
Abbott USD 6.65B 787M 2026-06
Acadia Pharmaceuticals USD 279.64M 36.37M 2026-06
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
Akebia Therapeutics USD 47.28M 1.7M 2025-12
Alnylam Pharmaceuticals USD 992.69M 167.68M 2026-06
AstraZeneca USD 12.86B 251M 2026-06
BioMarin Pharmaceutical USD 713.42M 142.21M 2026-06
Coherus Biosciences USD 8.7M 853K 2025-12
Eli Lilly USD 16.22B 301.7M 2026-03
Halozyme Therapeutics USD 297.47M 75.53M 2026-03
Illumina USD 770M 49M 2026-06
Insmed USD 356.19M 99.73M 2026-06
Ironwood Pharmaceuticals USD 85.24M 44.1M 2025-06
J&J USD 18.55B 1.31B 2026-06
Lexicon Pharmaceuticals USD 5.29M 8.88M 2025-12
MacroGenics USD 11.24M 19.87M 2026-03
MannKind USD 7.77M 60.56M 2026-06
Merck USD 12.09B 1.24B 2026-03
Moderna USD -566M 792M 2026-03
Novartis USD 11.24B 1.18B 2026-06
PTC Therapeutics USD 232.94M 84.56M 2026-03
Puma Biotechnology USD 20.32M 24.85M 2024-09
Sarepta Therapeutics USD 251.15M 370.2M 2026-06
Thermo Fisher Scientific USD 4.49B 146M 2026-03
Ultragenyx Pharmaceutical USD 180M 74M 2026-06
United Therapeutics USD 683.8M 35.7M 2026-06
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12